Compare Bristol-Myers Squibb Co (BMY) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Wells Fargo & Co — how do they compare? Bristol-Myers Squibb Co trades at $63.87 (market cap $129.94B), while Wells Fargo & Co trades at $88.98 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 2× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | WFC | |
|---|---|---|
Market Cap | $129.94B | $264.66B |
Sector | Health | Financials |
52-Week High | $65.89 | $96.40 |
52-Week Low | $42.60 | $73.42 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Wells Fargo (WFC) trades at $88.53, up 1.12% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $1.96, beating expectations, and maintains strong profitability with a net income margin of 25.97% and ROE of 13.13%. Recent news highlights the launch of tokenized deposits for corporate clients and a dividend increase to $0.50 per share, reflecting strategic innovation and shareholder returns.
The outlook for WFC is positive, supported by earnings beats, digital banking initiatives, and analyst consensus leaning toward buy. Risks include volatile cash flows, with 2025 operating cash flow negative $19.0B, and competitive pressures in the banking sector. The stock offers value with a P/E of 12.72, below industry averages, but investors should monitor execution on growth strategies and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
